{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007959","form_type":"8-K","ticker":null,"cik":"0001733294","company_name":"Generation Bio Co.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.800700+00:00","generated_at":"2026-06-02T02:30:44.962275+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Generation Bio Q1 net loss $74.5M on lease termination; cash runway into 2H 2027","bullets":["Q1 net loss $74.5M ($1.12/share) includes $56.9M non-cash lease termination charge; vs $32.1M ($0.53) Q1 2023.","Cash $233.9M at March 31, 2024; expected to fund operations into 2H 2027.","Presented in vivo T cell delivery data for ctLNP at ASGCT; advancing HSC-targeted ctLNP for sickle cell/beta-thalassemia.","R&D expenses $14.3M, down from $22.0M YoY; G&A $10.4M, down from $12.9M.","Collaboration with Moderna for T cell ctLNP; iqDNA platform using rapid enzymatic synthesis advanced."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007959","json":"https://secwatch.observer/filing/0001558370-24-007959.json","markdown":"https://secwatch.observer/filing/0001558370-24-007959.md","text":"https://secwatch.observer/filing/0001558370-24-007959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/0001558370-24-007959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/gbio-20240513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:30:44.962275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"98cfc8e5acfc586fe266ed4e3731b52af8e069f1","claim":"Generation Bio Co. reported the quarter ended March 31, 2024 results: net income Net loss was $74.5 million, or $1.12 basic and diluted net loss per share.","evidence_excerpt":"Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733294/000155837024007959/0001558370-24-007959-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $74.5 million, or $1.12 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}